Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392487 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL54952 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL3801411 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL9518805 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL3061 | 1.00 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL2896924 | 0.97 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL8614862 | 0.97 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL11373240 | 0.97 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL7652865 | 0.94 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL55986 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716978-B2 | FOR THERAPY AND PROHYLAXIS OF INFLAMMATORY DISEASES INCLUDING JOINT INFLAMMATION, CROHN'S DISEASE, AND INFLAMMATORY BOWEL DISEASE; RESPIRATORY DISEASES SUCH AS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING ASTHMA, CHRONIC BRONCHITIS | PFIZER INC | 2004-04-06 | — | — | US | claimed |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | WATSON JOHN W (US) | 2003-09-18 | — | — | US | claimed |
| US-20030158189-A1 | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | MARFAT ANTHONY (US) | 2003-08-21 | — | — | US | claimed |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | MARFAT ANTHONY (US) | 2002-05-16 | — | — | US | claimed |
| EP-1040829-A2 | Prokinetic agents for treating gastric hypomotility and related disorders | PFIZER INC. (US) | 2000-10-04 | — | — | EP | claimed |
| EP-1028946-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | claimed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | claimed |
| CN-109071750-B | Long-lasting cosmetic composition | 生活实验公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-113906032-A | Methods for preparing enantiomerically enriched JAK inhibitors | 康塞特医药品有限公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-111902139-A | Deuterated D-beta-hydroxybutyric acid analogs and uses thereof | 康塞特医药品有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-8748563-B2 | Curable compositions | HENKEL AG & CO. KGAA (DE) | 2014-06-10 | — | — | US | disclosed |
| US-20120301662-A1 | CURABLE COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2012-11-29 | — | — | US | disclosed |
| WO-2011047939-A1 | CURABLE COMPOSITION COMPRISING A BENZOXAZINE COMPOUND AND A SULFONIC ACID ESTER HAVING A CYCLIC STRUCTURE AS A HEAT-ACTIVATABLE CATALYST | HENKEL AG & CO. KGAA (DE) | 2011-04-28 | — | — | WO | disclosed |
| EP-1040829-A2 | Prokinetic agents for treating gastric hypomotility and related disorders | PFIZER INC. (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1028946-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1999023076-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0885890-A1 | SULFONYLUREIDOPYRAZOLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-4166827-A | DENTAL PLAQUE | COOPER LABORATORIES, INC. (US) | 1979-09-04 | — | — | US | disclosed |
| US-4100111-A | 1,10-SUBSTITUTED 1,10-DIAMINODECANES AS CURING AGENTS, HYDROGENATION OF 3,12-SUBSTITUTED 1,2-DIAZO-1,5,9-CYCLODODECATRIENES | CIBA-GEIGY CORPORATION (US) | 1978-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158189-A1 | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | PDE4B, PDE3B, PDE4A | ALDH1A1 1389/4885 |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | OPRM1, OPRK1, OPRD1 | ALDH1A1 1081/4885 |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PDE3B, ALPI, PDE4B | ALDH1A1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.